Taking a weekly 7 mg dose of rapamycin for early Alzheimer's doesn't vary too much from person to person, so doctors might not need to adjust doses or monitor blood levels in future studies.

44

Pro

0

Against

Evidence from Studies

Supporting (1)

44

Community contributions welcome

44

Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease

Cohort Study

Human

The study gave the same dose of rapamycin, on the same schedule, to Alzheimer’s patients and found that the drug levels in their blood didn’t vary too much from person to person, which means a standard dose could work for everyone without needing constant blood tests.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease

Score: 44

DOI: 10.1101/2025.03.18.25324017

Similar Assertions

For people with early Alzheimer’s taking a weekly 7 mg rapamycin pill, checking their blood 48 hours after the dose gives the most consistent results and best predicts their baseline levels—so that’s the best time to test it.

44

0

91%

People with early Alzheimer’s who take 7 mg of rapamycin every week seem to have low levels of the drug in their blood before their next dose—so low that it probably won’t weaken their immune system.

44

0

83%

When people with early Alzheimer's take rapamycin once a week, the drug stays in their body about as long as it does in other groups — around 69 hours — which means it leaves the body at a similar rate even with weekly dosing.

44

0

82%